Table 1 Demographic characteristics and clinical information of two disease groups
Dataset | Characteristic | Training cohort | Independent validation cohort | ||||
|---|---|---|---|---|---|---|---|
NPC group |  | NM (n = 84) | TM (n = 95) | p-Value | NM (n = 28) | TM (n = 31) | p-Value |
Sex | Â | Â | 0.903 | Â | Â | 0.398 | |
Male | 63 | 72 | Â | 21 | 26 | Â | |
Female | 21 | 23 | Â | 7 | 5 | Â | |
Mean age (SD) | 43.95 (11.72) | 45.40 (10.26) | 0.394 | 40.54 (9.74) | 45.10 (10.27) | 0.121 | |
Histologic grade |  |  | <  0.001* |  |  | 0.009* | |
I | 3 (3.57%) | 0 (0.0%) | Â | 1 (3.57%) | 0 (0.0%) | Â | |
II | 9 (10.72%) | 4 (4.21%) | Â | 6 (21.43%) | 2 (6.45%) | Â | |
III | 47 (55.95%) | 19 (20.0%) | Â | 14 (50.0%) | 8 (25.81%) | Â | |
IV | 25 (29.76%) | 72 (75.79%) | Â | 7 (25.0%) | 21 (67.74%) | Â | |
Metastatic sites |  |  | – |  |  | – | |
Lung | – | 36 (33.03%) |  | – | 11 (30.56%) |  | |
Liver | – | 30 (27.52%) |  | – | 12 (33.33%) |  | |
Bone | – | 43 (39.45%) |  | – | 13 (36.11%) |  | |
SLN group |  | NM (n = 60) | TM (n = 37) | p-Value | NM (n = 31) | TM (n = 18) | p-Value |
Mean age (SD) | 46.70 (11.85) | 46.59 (11.04) | 0.935 | 47.32 (9.18) | 50.33 (10.06) | 0.339 | |
Histologic grade | Â | Â | 0.261 | Â | Â | 0.254 | |
I | 7 (11.7%) | 2 (5.4%) | Â | 7 (22.6%) | 1 (5.6%) | Â | |
II | 23 (38.3%) | 20 (54.1%) | Â | 12 (38.7%) | 7 (38.9%) | Â | |
III | 30 (50.0%) | 15 (40.5%) | Â | 12 (38.7%) | 10 (55.6%) | Â | |
HER2 | Â | Â | 0.592 | Â | Â | 0.061 | |
Positive | 21 (35.0%) | 11 (29.7%) | Â | 6 (19.4%) | 8 (44.4%) | Â | |
Negative | 39 (65.0%) | 26 (70.3%) | Â | 25 (80.6%) | 10 (55.6%) | Â | |
Ki67 (SD) | 36.30 (24.34) | 26.32 (15.61) | 0.100 | 30.68 (25.19) | 35.06 (27.26) | 0.545 | |
ADC (SD) | 0.86 (0.20) | 0.82 (0.16) | 0.331 | 0.84 (0.16) | 0.86 (0.19) | 0.442 | |